This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Holt, R. I. Search for Related Content PubMed PubMed Citation Articles by Holt, R. I. Social Bookmarking                         What's this?

Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists

Endocrinology and Metabolism Subdivision, Developmental Origins of Health and Disease, School of Medicine, University of Southampton, Southampton, UK, righ{at}soton.ac.uk

Hyperprolactinaemia is the commonest endocrine disorder of the hypothalamic—pituitary axis and can lead to both short-term sexual dysfunction and galactorrhoea, and long-term loss of bone mineral density. Prolactin is secreted from the anterior pituitary gland under the influence of dopamine, which exerts a tonic inhibitory effect on prolactin secretion. Physiological regulators of prolactin secretion include many different types of `stress' and sleep. Disruption of the normal control of prolactin secretion results in hyperprolactinaemia from pathological and pharmacological causes. The administration of antipsychotic medication is responsible for the high prevalence of hyperprolactinaemia in people with severe mental illness. Physiological hyperprolactinaemia, such as pregnancy and lactation, should be distinguished from pathological causes to prevent unnecessary investigation and treatment. The causes, consequences and management of hyperprolactinaemia are discussed in this article.

Key Words: prolactin • prolactinoma • antipsychotic • dopamine

Journal of Psychopharmacology, Vol. 22, No. 2 suppl, 28-37 (2008)
DOI: 10.1177/0269881107087951


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Churchward, S. M. Oxborrow, V. O. Olotu, and M. D. Thalitaya Setting standards for physical health monitoring in patients on antipsychotics The Psychiatrist, December 1, 2009; 33(12): 451 - 454. [Abstract] [Full Text] [PDF]

				V. O'Keane Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia J Psychopharmacol, March 1, 2008; 22(2_suppl): 70 - 75. [Abstract] [PDF]

				J. Walters and I. Jones Clinical questions and uncertainty -- prolactin measurement in patients with schizophrenia and bipolar disorder J Psychopharmacol, March 1, 2008; 22(2_suppl): 82 - 89. [Abstract] [PDF]

				R. C Peveler, D. Branford, L. Citrome, P. Fitzgerald, P. W Harvey, R. I. Holt, L. Howard, D. Kohen, I. Jones, V. O'Keane, et al. Antipsychotics and hyperprolactinaemia: Clinical recommendations J Psychopharmacol, March 1, 2008; 22(2_suppl): 98 - 103. [PDF]